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Shorter survival has been associated with low socioeconomic status (SES) among elderly non-Hodgkin’s lymphoma (NHL)
patients; however it remains unknown whether the same relationship holds for younger patients. We explored the California
Cancer Registry (CCR), to investigate this relationship in adolescent and young adult (AYA) NHL patients diagnosed from 1996
to 2005. A case-only survival analysis was conducted to examine demographic and clinical variables hypothesized to be related
to survival. Included in the ﬁnal analysis were 3,489 incident NHL cases. In the multivariate analyses, all-cause mortality (ACM)
was higher in individuals who had later stage at diagnosis (P<. 05) or did not receive ﬁrst-course chemotherapy (P<. 05). There
was also a signiﬁcant gradient decrease in survival, with higher ACM at each decreasing quintile of SES (P<. 001). Overall results
were similar for lymphoma-speciﬁc mortality. In the race/ethnicity stratiﬁed analyses, only non-Hispanic Whites (NHWs) had a
signiﬁcant SES-ACM trend (P<. 001). Reduced overall and lymphoma-speciﬁc survival was associated with lower SES in AYAs
with NHL, although a signiﬁcant trend was only observed for NHWs.
1.Introduction
Lymphomas are among the most common cancers [1]
and the most common hematologic malignancy [2]i n
adolescents and young adults (AYAs, deﬁned by the National
Cancer Institute (NCI) as individuals aged 15–39 at diag-
nosis). In California, non-Hodgkin’s lymphoma (NHL)
represents approximately 7% of cancers diagnosed in AYAs
(unpublished data). Mortality in AYA NHL patients has been
foundtobehigherthaninyoungerchildren[3,4],attributed
in part to a lack of understanding of how best to treat NHL
in AYAs.
Recent attention has been given to investigating socioe-
conomic disparities in survival among cancer patient pop-
ulations with diverse ethno-racial or socioeconomic back-
grounds or with diﬀerential access to healthcare [5–10].
Concurrently, NCI—as well as several other cancer advocacy
agencies such as the Lance Armstrong Foundation—has
begun to address the gaps in cancer research for AYAs [1, 11].
This study sought to examine whether socioeconomic
factors beyond race/ethnicity and treatment diﬀerences
inﬂuence survival in AYAs with NHL. The following research
questions were investigated:
(1) Does neighborhood-level socioeconomic status
(nSES) at diagnosis predict all-cause and lymphoma-
speciﬁc mortality in AYAs diagnosed with NHL,
after adjustment for race/ethnicity, gender, insurance
status at diagnosis, marital status, stage at diagnosis,
nodality, and ﬁrst-course treatment?
(2) Is there a linear trend between decreasing nSES and
shorter survival?
(3) Is the relationship between nSES and mortality
modiﬁed by race/ethnicity?2 Journal of Cancer Epidemiology
2. Patientsand Methods
2.1. Study Population. A retrospective case-only analysis was
performed of NHL cases diagnosed in California between
1996 and 2005 among individuals aged 15 to 39 years
old using the California Cancer Registry (CCR) (N =
3,762). The CCR, has been part of the NCI’s Surveillance,
Epidemiology and End Results (SEER) program since 1988
[12–15] with annual patient follow-up [16]. Data were
abstracted from medical and laboratory records [14], with
tumorsiteandhistologycodedusingtheWorldHealthOrga-
nization (WHO) criteria in the International Classiﬁcation
of Diseases for Oncology (ICD-O, 3rd edition) [17]. Patient
cases were selected according to ICD-O-3 coding standards
andbasedonhistologictypesfornodalandextranodalNHL:
SEER primary site codes 33041 and 33042. Histologic types
included Burkitt’s (n = 228), diﬀuse large B-cell (n = 1,746),
follicular(n=480),lymphoblastic,(n=201),anaplasticlarge
cell (n = 148), and other types (n = 950).
Seventy-eight cases were identiﬁed only through death
certiﬁcate, obituary, or the Social Security Death Index, and
an additional two were lost to follow-up. The remaining
cases were identiﬁed through hospitals, inpatient/outpatient
centers, oncology treatment centers, laboratories, or private
practitioners.
Recorded variables in the CCR include age at diagnosis,
demographic information, histology, ﬁrst-course therapy
(radiation, chemotherapy, and surgery status), neighbor-
hood SES (nSES), vital status, treatment hospital type (pedi-
atric or otherwise), and insurance status. For this analysis,
health insurance status at diagnosis was categorized in one
of the four following ways: (1) private insurance (including
managed care, military and Veterans Administration, or
other private); (2) government-funded insurance (including
Medicare, Medicaid, or other state assistance programs); (3)
no insurance; or (4) unknown insurance status. Individuals
with government-provided insurance were not grouped
with those who had private insurance because prelimi-
nary Kaplan-Meier analyses indicated that individuals with
government-provided insurance had shorter survival than
individuals without health insurance at diagnosis, corrob-
orating previously published reports [18–20]. Race and
ethnicity was also abstracted from patient medical records
[14]. The following four categories were used in the analysis:
Non-Hispanic White (NHW), Non-Hispanic Black (NHB),
Hispanic/Latino (HL), and Asian/Paciﬁc Islander (API). The
nSES variable used in the CCR is a single index created
from a principle component analysis of census block group-
level measures of education, income, occupation, and an
adjustment for cost of living, previously described [21].
Quintiles for the nSES score were included for analysis. A
subgroup analysis was performed on individuals aged 18
and over at diagnosis to examine the additional predictor
of marital status at diagnosis, after all other variables were
included in the model.
2.2. Cause of Death. Cause of death was recorded according
to the ICD criteria in eﬀect at the time of death [17], using
ICD-9 codes for deaths prior to 2000 and ICD-10 codes for
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Figure 1: Racial/ethnic breakdown of frequency of neighborhood-
level socioeconomic status (nSES).
deaths in 2000 and later. Hospital registrars contact cases
annually and CCR staﬀ review state death certiﬁcates on an
annual basis to identify deceased patient cases. The last date
offollow-upwasthedateofdeathorlastdateofcontact[13].
2.3. Statistical Analyses. Demographic characteristics and
clinical parameters were analyzed using Pearson’s χ2
tests. Kaplan-Meier curves were generated for age group,
race/ethnicity, nSES categories, and insurance status and
were compared with the log-rank test. Cox proportional
hazardregressionwasperformedtogenerateadjustedhazard
ratios (HRs) for all-cause mortality (ACM) and lymphoma-
speciﬁc mortality (LSM) using SAS 9.1 (SAS Institute, Inc.,
Cary, NC), controlling for age at diagnosis, race/ethnicity,
histology, stage at diagnosis, nSES, insurance status, gender,
and diagnostic year. Statistical signiﬁcance was assumed for
a two-tailed P = .05.
3. Results
3.1. Demographic Data. A total of 2,432 males and 1,330
females in California aged 15–39 at diagnosis with NHL
between 1996 and 2005 comprised the study group. Table 1
presents distributions of demographic, clinical, and socioe-
conomic characteristics by race/ethnicity. There was signif-
icant variation in age, tumor staging, nodality, ﬁrst-course
chemotherapy, radiation, nSES, and health insurance. The
majority of the cases (all histologic types) were diagnosed at
a late stage, but signiﬁcantly more (P<. 01) Non-Hispanic
Black (52%) than Asian/Paciﬁc Islander (34.7%) patients
were diagnosed at a distant stage.
Figure 1 presents the frequencies of nSES at diagnosis
by race/ethnicity and shows that for NHWs and APIs, more
individuals resided in higher SES areas, while for NHBs andJournal of Cancer Epidemiology 3
Table 1: Demographic and clinical characteristics of adolescents and young adults diagnosed with non-Hodgkin’s lymphoma
a.
Characteristic
Non-Hispanic
White
n = 1,930
n (%)
Non-Hispanic
Black
n = 281
n (%)
Hispanic/
Latino
n = 1,131
n (%)
Asian/Paciﬁc
Islander
n = 380
n (%)
Other
n = 40
n (%)
Total
N=3,762 P
Age at Diagnosis
15–29 613 (31.8) 108 (38.4) 461 (40.8) 168 (44.2) 10 (25) 1360 (36.2) <.0001
30–39 1317 (68.2) 173 (61.6) 670 (59.2) 212 (55.8) 30 (75) 2402 (63.9)
Mean Age (SD) 31.5 (6.5) 30.5 (6.7) 30.2 (6.7) 29.4 (7.0) 32.4 (6.4) 30.8 (6.6)
Year of Diagnosis
1996–2000 1022 (53) 138 (49.1) 530 (46.9) 173 (45.5) 16 (40) 1879 (50.0) .0031
2001–2005 908 (47) 143 (50.9) 601 (53.1) 207 (54.5) 24 (60) 1883 (50.0)
Gender
Male 1265 (65.5) 181 (64.4) 741 (65.5) 222 (58.4) 23 (57.5) 2432 (64.7) .078
Female 665 (34.5) 100 (35.6) 390 (34.5) 158 (41.6) 17 (42.5) 1330 (35.4)
Tumor stage
Local 553 (28.7) 69 (24.6) 346 (30.6) 141 (37.1) 18 (45) 1127 (30.0) <.0001
Regional 372 (19.3) 47 (16.7) 202 (17.9) 89 (23.4) 4 (10) 714 (19.0)
Distant 905 (46.9) 146 (52) 526 (46.5) 132 (34.7) 10 (25) 1719 (45.7)
Unknown 100 (5.2) 19 (6.8) 57 (5) 18 (4.7) 8 (20) 202 (5.4)
Nodality
Nodal 1384 (71.7) 187 (66.5) 729 (64.5) 227 (59.7) 19 (47.5) 2546 (67.7) <.0001
Extranodal 546 (28.3) 94 (33.5) 402 (35.5) 153 (40.3) 21 (52.5) 1216 (32.3)
First-course Chemotherapy
Yes 1560 (80.8) 229 (81.5) 946 (83.6) 302 (79.5) 21 (52.5) 3058 (81.3) <.0001
No 343 (17.8) 51 (18.1) 175 (15.5) 74 (19.5) 19 (47.5) 662 (17.6)
Unknown 27 (1.4) 1 (0.4) 10 (0.9) 4 (1.1) — 42 (1.1)
First-course Radiation
Yes 669 (34.7) 89 (31.7) 317 (28) 159 (41.8) 11 (27.5) 1245 (33.1) <.0001
No 1261 (65.3) 192 (68.3) 814 (72) 221 (58.2) 29 (72.5) 2517 (66.9)
nSES
Highest 548 (28.4) 20 (7.1) 95 (8.4) 132 (34.7) 16 (40) 811 (21.6) <.0001
High 489 (25.3) 47 (16.7) 144 (12.7) 92 (24.2) 8 (20) 780 (20.7)
Middle 425 (22) 64 (22.8) 201 (17.8) 71 (18.7) 10 (25) 771 (20.5)
Low 302 (15.6) 76 (27) 288 (25.5) 43 (11.3) 1 (2.5) 710 (18.9)
Lowest 166 (8.6) 74 (26.3) 403 (35.6) 42 (11.1) 5 (12.5) 690 (18.3)
Insurance
Managed Care or Private
Insurance (including
Military/Veterans
Aﬀairs)
1376 (71.3) 156 (55.5) 539 (47.7) 283 (74.5) 27 (67.5) 2381 (56.2) <.0001
Medicaid/Medicare/
Government Assistance 333 (17.3) 84 (29.9) 356 (31.5) 54 (14.2) 4 (10) 831 (19.6)
Not Insured 65 (3.4) 12 (4.3) 98 (8.7) 15 (3.9) 1 (2.5) 191 (4.5)
Unknown 333 (17.3) 84 (29.9) 356 (31.5) 54 (14.2) 4 (10) 831 (19.6)
aSource: California Cancer Registry. Individuals diagnosed between January 1, 1996 and December 31, 2005.
Abbreviations: SD: standard deviation; nSES: neighborhood socioeconomic status.4 Journal of Cancer Epidemiology
HLs, the opposite trend was true. For the remaining survival
analyses, individuals with unknown race/ethnicity, stage, or
chemotherapy status were excluded (N = 183).
3.2. Cause of Death. During the follow-up period through
December2005,1,081deathsoccurredamongthetotal3,489
patients included in this analysis. The majority of deaths
were due to lymphoma-related causes (N = 593; ICD-9
codes: 2008, 2019, 2028, ICD-10 codes: C819, C829, C833-
5, C837, C844-5, C851, C859). The second most common
cause of death was human immunodeﬁciency virus (HIV)
disease resulting in NHL (N = 204; ICD-9 code: 042,
ICD-10 codes: B21.0-3, B21.7-8); an additional 43 died due
to HIV complications that led to noncancerous diseases
(ICD-10 code: B227). Twenty-four others died of lymphoid
leukemia (ICD-9 code: 204.0, ICD-10 codes: C91.0-5), and
the remaining deaths were due to other causes (N = 217).
3.3. Survival Analysis. Table 2 displays the unadjusted and
adjusted hazard ratios for both all-cause mortality (ACM)
and lymphoma-speciﬁc mortality (LSM) for this analysis.
The estimated average HR increased by 2% (95% CI: 1.01–
1.03)foreveryincreasingyearofageatdiagnosisafteradjust-
mentforallothervariables:gender,race/ethnicity,diagnostic
year, histological subtype, nodality, stage at diagnosis, nSES,
insurance status at diagnosis, and ﬁrst-course treatment with
chemotherapy and/or radiation. In the univariate model,
NHBs and HLs appeared to have increased ACM and
LSM compared to NHWs. However, after adjustment no
signiﬁcantdiﬀerences in mortality remained between NHWs
and either NHBs or HLs. Conversely, adjustment increased
rather than decreased the magnitude of diﬀerence in LSM
for APIs compared to NHWs.
Compared to earlier stages, later stage at diagnosis
appeared to have a slightly stronger eﬀect on ACM after
adjustment (adj HR: 3.16, 95% CI: 2.63–3.81) and the
adjusted HR for later stage at diagnosis remained high
for LSM (adj HR: 3.14, 95% CI: 2.42–4.06). Extranodal
involvement appeared to increase risk of overall death, but
only after adjustment (adj HR: 1.29, 95% CI: 1.11–1.50). For
LSM, extranodal involvement appeared to have a protective
eﬀect(HR:0.71,95%CI:0.59–0.86),buttherewasalmostno
eﬀect after adjustment (adj HR: 0.99, 95% CI: 0.81–1.22).
Not having received chemotherapy as a ﬁrst-course
treatment appeared protective in the unadjusted ACM
analysis (HR: 0.75, 95% CI: 0.62–0.91), but in the full
model conferred shorter ACM (adj HR: 1.27, 95% CI: 1.02–
1.57).Onthecontrary,nothavingﬁrst-coursechemotherapy
yielded protective LSM eﬀects for both the unadjusted
(HR: 0.24, 95% CI: 0.16–0.36) and adjusted HR (adj HR:
0.37, 95% CI 0.24–0.57). Results were stratiﬁed by stage at
diagnosis, and it appears that only in patients with distant-
staged NHL was adjusted ACM signiﬁcantly higher than
in patients that did not receive ﬁrst-course chemotherapy
(adj HR: 1.69, 95% CI 1.28–2.24). For patients who did not
receive ﬁrst-course chemotherapy, LSM was improved both
in those with localized disease (adj HR: 0.16, 95% CI 0.07–
0.38) and those with regional disease (adj HR: 0.11, 95%
0
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Figure 2: Unadjusted Kaplan-Meier survival curves (N=3,489) by
neighborhood-level socioeconomic status (nSES).
CI 0.01–0.76). Not receiving ﬁrst-course radiation therapy
yielded signiﬁcantly worse hazard ratios for the unadjusted
ACM(HR:1.31,95%CI1.15–1.50)andLSM(HR:1.43,95%
CI: 1.19–1.71) estimates, but did not have a signiﬁcant eﬀect
after adjustment.
The eﬀects of decreasing nSES on ACM and LSM signif-
icantly worsened with every decreasing quintile both before
and after adjustment, with the strongest eﬀects evident at the
lowest quintile (P<. 05) (see Figure 2 for overall unadjusted
Kaplan-Meier survival curves). The adjusted hazard ratio
for ACM for those residing in the poorest SES quintile at
diagnosis compared to the wealthiest was 1.40 (95% CI:
1.13–1.75). All-cause mortality was higher for individuals
with government-provided insurance as compared to having
no insurance (HR: 1.41, 95% CI: 1.07–1.87), but after
adjustment the eﬀect was only marginally signiﬁcant (adj
HR: 1.32, 95% CI: 1.00–1.75). For individuals with private
insurance,unadjustedsurvivalwaslonger(HR:0.62,95%CI:
0.47–0.82) compared to those without insurance, although
the diﬀerence was not signiﬁcant after adjustment.
A subgroup analysis was conducted to examine whether
marital status, as a means of social support, conferred longer
survival among individuals aged 18 and over at diagnosis.
After adjustment for the other demographic and clinical
parameters in the full model, individuals who were married
at diagnosis had 23% lower ACM (adj HR: 0.67, 95% CI:
0.58–0.78) as compared to those who were single, separated,
divorced, or widowed at diagnosis. There was no signiﬁcant
diﬀerenceinlymphoma-speciﬁcsurvivalforindividualswho
were married at diagnosis, as compared to other marital
statuses (adj HR: 1.00, 95% CI: 0.83–1.20).
3.4. Race/Ethnicity-Speciﬁc Multivariate Survival Analysis.
Overall survival analysis was next stratiﬁed by the four
racial/ethnic groups: NHW, NHB, HL, and API (Table 3). In
the stratiﬁed analysis, a one-year diﬀerence in age conferred
a signiﬁcant survival eﬀect only in NHWs (adj HR: 1.02,
95% CI: 1.01–1.04) and HLs (adj HR: 1.02, 95% CI: 1.01–
1.04); however, the analyses may have been underpowered
for NHBs and APIs. Later stage at diagnosis continued to
be the strongest predictor of mortality across all age groups.Journal of Cancer Epidemiology 5
Table 2: Multivariate hazard ratios
a for all-cause mortality
b and lymphoma-speciﬁc mortality
c using Cox Proportional Hazards model for
adolescent and young adult non-Hodgkin’s lymphoma patients.
ACM LSM
Characteristic Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Sex
Male 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Female 0.54 (0.47–0.63)∗ 0.65 (0.57–0.75)∗ 0.79 (0.66-0.93)∗ 0.93 (0.78–1.11)
Age at Diagnosis
By year 1.01 (1.00–1.02)∗ 1.02 (1.01–1.03)∗ 0.99 (0.98–1.00) 1.00 (0.99–1.01)
Race/Ethnicity
Non-Hispanic
White 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Non-Hispanic Black 1.50 (1.20–1.86)∗ 1.13 (0.90–1.41) 1.38 (1.03–1.86)∗ 1.11 (0.82–1.51)
Hispanic/Latino 1.30 (1.13–1.49)∗ 1.07 (0.92–1.25) 1.27 (1.06–1.53) 1.08 (0.88–1.32)
Asian/Paciﬁc
Islander 0.86 (0.68–1.08) 0.99 (0.78–1.26) 1.35 (1.04–1.74)∗ 1.52 (1.17–1.98)∗
Stage
Local 1.00 (Ref)† 1.00 (Ref)† 1.00 (Ref)† 1.00 (Ref)†
Regional 1.16 (0.93–1.45) 1.28 (1.02–1.62)∗ 1.85 (1.39–2.47)∗ 1.62 (1.21–2.18)∗
Distant 2.94 (2.50–3.46) 3.16 (2.63–3.81)∗ 3.68 (2.91–4.65)∗ 3.14 (2.42–4.06)∗
Nodality
Nodal 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Extranodal 1.03 (0.90–1.17) 1.29 (1.11–1.50)∗ 0.71 (0.59–0.86)∗ 0.99 (0.81–1.22)
First-course
Chemotherapy
Yes 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
No 0.75 (0.62–0.91)∗ 1.27 (1.02-1.57)∗ 0.24 (0.16–0.36)∗ 0.37 (0.24–0.57)∗
First-course Radiation
Yes 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
No 1.31 (1.15–1.50) 0.94 (0.82–1.09) 1.43 (1.19–1.71)∗ 1.01 (0.83–1.22)
nSES
Highest 1.00 (Ref)† 1.00 (Ref)† 1.00 (Ref)† 1.00 (Ref)†
High 1.22 (0.98–1.50) 1.15 (0.93–1.42) 1.07 (0.81–1.41) 1.08 (0.81–1.41)
Middle 1.33 (1.08–1.63)∗ 1.20 (0.97–1.48) 1.27 (0.98–1.66) 1.21 (0.93–1.59)
Low 1.67 (1.37–2.05)∗ 1.39 (1.12–1.71)∗ 1.62 (1.26–2.10)∗ 1.49 (1.14–1.96)∗
Lowest 1.97 (1.62–2.40)∗ 1.40 (1.13–1.75)∗ 1.70 (1.31–2.20)∗ 1.38 (1.04–1.84)∗
Insurance
None 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Managed or Private 0.62 (0.47–0.82)∗ 0.82 (0.62–1.08) 0.74 (0.52–1.07) 0.96 (0.66–1.39)
Government 1.41 (1.07–1.87)∗ 1.32 (1.00–1.75) 1.24 (0.85–1.81) 1.16 (0.79–1.70)
Unknown 0.87 (0.63–1.21) 0.96 (0.69–1.33) 0.88 (0.57–1.37) 0.89 (0.65–1.20)
Source: California Cancer Registry. Individuals diagnosed between January 1, 1996 and December 31, 2005. Abbreviations: nSES: neighborhood
socioeconomic status, ACM: all-cause mortality, LSM: lymphoma-speciﬁc mortality, HR: hazard ratio, CI: conﬁdence interval, Ref: reference.
aAll adjusted hazard ratios are fully adjusted for the other variables in the model, in addition to major histology (Burkitt’s, follicular, lymphoblastic, diﬀuse
largeB-cell,anaplastic,andother/unknown)anddiagnosticyear.Resultsforindividualswithrace/ethnicityotherthanwhatislisted(N =40),orcasesmissing
data for stage (N = 202) or chemotherapy (N = 42) were excluded from analysis.
bACM: N = 3,489, with 1,081 deaths.
cLSM: N = 3,489, with 593 deaths.
∗Test for signiﬁcance at α = 0.05.
†Test for trend signiﬁcant at α = 0.05.6 Journal of Cancer Epidemiology
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Extranodal involvement was a signiﬁcant adverse risk factor
only for NHWs (adj HR: 1.51, 95% CI: 1.21–1.87).
Notreceivingﬁrst-coursechemotherapywasasigniﬁcant
adverse risk factor in NHBs (adj HR: 2.02, 95% CI: 1.09–
3.71) and HLs (adj HR: 1.71, 95% CI: 1.19–2.46), but
interestingly, a signiﬁcant protective factor in APIs (adj
HR: 0.25, 95% CI: 0.08–0.74). Not receiving ﬁrst-course
radiation therapy was not a signiﬁcant hazard for any of
theracial/ethnicgroups.Afterstratiﬁcationbyrace/ethnicity,
decreasing nSES was associated with worse ACM in NHWs,
with the middle (adj HR: 1.33, 95% CI: 1.01–1.75), low (adj
HR: 1.62, 95% CI: 1.22–2.14), and lowest (adj HR: 2.25, 95%
CI: 1.64–3.08) quintiles having signiﬁcantly higher hazard
of overall death than the highest. A linear trend test was
signiﬁcant (P<. 001). Having private insurance imparted a
protective eﬀect only for HLs (adj HR: 0.64, 95% CI: 0.43–
0.95), and having government-provided insurance predicted
worse ACM in NHBs (adj HR: 5.97, 95% CI: 1.41–25.24).
4. Discussion
This study is one of the ﬁrst to examine the impact of
socioeconomic status on survival in adolescents and young
adults with non-Hodgkin’s lymphoma. Our analyses
indicate that nSES and treatment variables attenuate
much of the racial/ethnic-speciﬁc diﬀerences in survival
and that, after adjustment for demographic and clinical
variables, both NHBs and HLs tend to show similar survival
patterns to NHWs. Asian/Paciﬁc Islanders, however, showed
signiﬁcantly poorer lymphoma-speciﬁc survival than
NHWs. Being married at diagnosis, a possible indicator of
social support [22], as compared to being single, separated,
widowed, or divorced, conferred strong protection against
all-cause mortality, but not lymphoma-speciﬁc mortality.
Furthermore, when examined across racial/ethnic
groups, a signiﬁcant gradient in survival by nSES was only
evident in NHWs. Although not signiﬁcant, there was a sug-
gestion of lower survival in APIs as nSES decreased, but the
low numbers of APIs in the study likely contributed to wide
conﬁdence intervals. For HLs, having private insurance con-
tributedtobettersurvival,butforNHB,havinggovernment-
provided insurance was associated with worse survival.
Similar ﬁndings were reported in a cohort of elderly
NHL patients (age at diagnosis ≥ 65) in a study examining
the association of mortality risk and SES. Over three times
as many Black patients resided in the lowest SES quartile
than Whites (P<. 001). The authors found increasing
hazard ratios by decreasing SES quartile after adjusting for
race/ethnicity, sex, age, marital status, stage, comorbidity,
and therapy, and for both all-cause and NHL-speciﬁc
mortality.Interestingly,individualsinthelowestSESquartile
and diagnosed at stages I-II had a higher adjusted hazard
ratio (adj HR: 1.31, 95% CI: 1.19–1.44) than individuals
diagnosed at stages III-IV (adj HR: 1.22, 95% CI: 1.12–
1.33). Finally, after controlling for disparities in stage at
diagnosisandtreatment,theauthorsfailedtoﬁndsigniﬁcant
diﬀerences in all-cause or NHL-speciﬁc mortality between
Black and White patients [10].
A Brazilian study of Hodgkin’s lymphoma patients also
found higher mortality associated with lower SES that was
unexplained by treatment regimen [23]. A Scandinavian
study investigated SES inﬂuences on incidence and survival
in adult NHL cases and found decreasing rates of both
one- and ﬁve-year relative survival by decreasing level of
education, dwelling size, and disposable income [24].
However,twootherstudiesofSESimpactsonlymphoma
survival failed to ﬁnd a signiﬁcant association. A hospital-
based study in Austria that investigated relapse-free survival
(RFS) in a cohort of 218 Hodgkin’s lymphoma patients
(average age at diagnosis = 35.9 ± 15.0 years) found that
afteradjustmentforagesurvivalratesactuallydecreasedwith
corresponding increases in educational level and income.
The authors commented that the ﬁndings seemed to be
speciﬁc only to Hodgkin’s patients and may partly be speciﬁc
to Austria’s equal-access healthcare system or to possible
underlying immunological diﬀerences related to life-course
exposures, such as Epstein-Barr virus positivity [25]. A
study on teenaged and young adult cancer patients (aged
13–24) in England reported no gradient between survival
and a composite measure of area-level poverty among NHL
patients [26]. The lack of an association may be partly due
to the age range included in this study; another study that
examined nSES impacts on survival in leukemia patients
aged 0–39 only found a signiﬁcant gradient in survival
among 30–39 year-olds [9].
An investigation on survival in NHL patients in Scotland
and Wales found 10% and 19% shorter survival in interme-
diate and most deprived areas, respectively, [27]. The study
used an area-level deprivation score based on four census
variables (car ownership, male unemployment, overcrowd-
ing, and social class). Race and ethnicity were not reported
in the Scottish study, perhaps because health research on
racial/ethnic diﬀerences in survival is less widely conducted
in the UK. If the study sample was fairly homogenously
Caucasian, the results would be consistent with our ﬁndings
ofannSESgradientinsurvivalamongNon-HispanicWhites.
Not ﬁnding an SES-mortality gradient in the non-White
patientsinourstudyraisesseveralquestionsaboutthecancer
experience in these populations. First, it is important to
reiterate that for NHBs and HLs, although the unadjusted
hazard ratios for both ACM and LSM were signiﬁcantly
higher than for NHWs, adjustment for the other factors
in the model—including nSES, stage at diagnosis, and
ﬁrst-course treatment—attenuated these risks. As evident
in Figure 1, there were far more NHBs and HLs residing
in poorer nSES areas, which often have lower access to
resources. Thus, it is possible the diﬀerences in survival
by race/ethnicity commonly reported may be due more
to confounding by later initiation of and poorer access to
care, a phenomenon noted in Hispanic populations [28].
Measuring access to care is quite diﬃcult, particularly in
a registry-based analysis, and further studies should be
done to examine why a gradient exists for NHWs but not
other racial/ethnic groups. Diﬀerential access to the most
eﬀective treatment regimens may still persist for lower SES
groups.8 Journal of Cancer Epidemiology
The lack of a consistent association between health
insurance status and survival after adjustment was surpris-
ing, given the widely-documented increased vulnerability of
patients lacking health insurance. Finding higher all-cause
mortalityamongthosewithgovernment-providedinsurance
comparedtothosewithoutinsurancesuggeststhattheremay
be important disparities in access to care among Medicaid
recipients. Approximately double the percentage (17.8%)
of those without health insurance compared to those with
government-provided health insurance (9.4%) resided in the
highest nSES quintile at diagnosis. A paper analyzing the
relationship of health insurance status and cancer outcomes
across US demographic groups found striking disparities
in cancer screening, stage at diagnosis, and survival for
those uninsured or insured by Medicare or Medicaid [19].
Individuals in the general population aged 18–24 were also
found to have the highest probability of lacking insurance
or being insuﬃciently insured. Access to adequate healthcare
coveragecanaﬀectcancercare,includingchallengesofcover-
ing premiums, deductibles, and co-payments, and diﬃculty
remaining employed and eligible for insurance beneﬁts [19,
29]. One study found an average increase of 13.1 weeks
in wait time between diagnosis and initiation of treatment
for non- or government-insured patients as compared to
private health insurance, although no associations between
wait times and SES, gender, age, race/ethnicity, or marital
status were found [30]. These ﬁnancial considerations may
contribute to delays and advanced staging at diagnosis.
One of the strengths of this study is the use of CCR data
with a large, heterogeneous, and population-based cohort
with almost complete patient ascertainment and follow-
up. Registry-based explorations of factors that contribute to
longer survival are important to help identify groups that
are particularly vulnerable to premature cancer mortality.
Because social determinants aﬀect health outcomes along
several pathways, it is important to document the existence
of persistent health disparities, particularly for understudied
groups such as AYAs.
The limitations of this study include the estimation of
SES based on the residence at diagnosis, which may not
accurately capture some factors that contribute to healthy
living environments and adequate medical care. Transition-
ing through developmental life stages can make AYAs a
heterogeneous group; some are dependent on parents and
relatives while others provide for families of their own. As
such, measuring SES as a one-time neighborhood composite
variable may inadequately summarize an individual patient’s
social and ﬁnancial circumstances [31]. The way that ﬁrst
course of treatment is measured in the Registry is also
somewhat limited; it is not possible to know the type of
therapy, the dose-intensity administered, and other factors
related to the treatment regiment that may have signiﬁcant
inﬂuence on survival. Furthermore, knowing a patient’s
health insurance status only at diagnosis does not reveal
whether the insurance was suﬃcient in covering the costs
associated with cancer treatment, nor does it reveal whether
there were any subsequent lapses in insurance coverage.
These ﬁndings do not appear to be limited to the US;
however, comparability across borders may be limited due to
diﬀering national health systems. Patient contact studies that
address individual socioeconomic barriers to treatment and
recoveryandthatcanbetterguidepotentialinterventions are
warranted,asisthedevelopmentandevaluationofprograms
speciﬁcally designed to meet the needs of the diverse and
unique AYA population.
5. Conclusion
Our study is one of the ﬁrst to examine socioeconomic
impacts on survival in AYAs with NHL. We determined that
as neighborhood SES at diagnosis increases, overall- and
lymphoma-speciﬁc survival improves, after adjustment for
demographic and treatment variables, and a linear trend
persists. The impact of SES on mortality appeared to be
independent of health insurance status at diagnosis. How-
ever, when stratiﬁed by race/ethnicity, the eﬀects of nSES on
mortality were only signiﬁcant in Non-Hispanic Whites.
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